secwatch.observer — SEC 8-K summary
======================================

Issuer:     Tarsus Pharmaceuticals, Inc. (TARS)
CIK:        0001819790
Form:       8-K
Filed at:   2026-07-13T20:11:59+00:00
Accession:  0001819790-26-000048
Event type: leadership
Sentiment:  neutral
Materiality: 0.55
Item codes: 5.02
LLM model:  deepseek-v4-flash:cloud@v2

Tarsus CCO Aziz Mottiwala departing July 15 to become CEO of another public med device company
--------------------------------------------------------------------------------

- Aziz Mottiwala to leave role as Chief Commercial Officer and employment on July 15, 2026.
- Mottiwala is departing to become CEO of a public medical device company.
- No successor or interim CCO has been announced by Tarsus Pharmaceuticals.
- Announcement made on July 13, 2026; departure is voluntary for an external CEO opportunity.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1819790/000181979026000048/0001819790-26-000048-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1819790/000181979026000048/tars-20260713.htm
  HTML page:      https://secwatch.observer/filing/0001819790-26-000048

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer